Skip to search formSkip to main contentSkip to account menu

improgan

National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

SKF 92374

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2009
2009
Non-opioid antinociception produced by brain stem injections of improgan: Significance of local, but not cross-regional, cannabinoid mechanisms
2007
2007
CC12, a high-affinity ligand for [3H]cimetidine binding, is an improgan antagonist
2006
2006
Cannabinoid-improgan cross-tolerance: Improgan is a cannabinomimetic analgesic lacking affinity at the cannabinoid CB1 receptor.
2004
2004
Effects of cimetidine-like drugs on recombinant GABAA receptors.
2003
2003
Improgan antinociception does not require neuronal histamine or histamine receptors
2002
2002
Inhibition of Improgan Antinociception by the Cannabinoid (CB)1 AntagonistN-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): Lack of…
Improgan, a nonopioid antinociceptive agent, activates descending, pain-relieving mechanisms in the brain stem, but the receptor… 
2001
2001
Significance of GABAergic systems in the action of improgan, a non-opioid analgesic.
2001
2001
A role for spinal, but not supraspinal, α2 adrenergic receptors in the actions of improgan, a powerful, non-opioid analgesic
2000
2000
Antinociceptive Activity of Derivatives of Improgran and Burimamide
1998
1998
Antinociceptive activity of impentamine, a histamine congener, after CNS administration.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)